Critique on "Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification".
作者信息
Javed Arooha, Savez Syed Muhammad, Rayyan Syed Muhammad
机构信息
Dow Medical College, Karachi, Pakistan.
Bahria University of Health Sciences, Karachi, Pakistan.
出版信息
Clin Cardiol. 2025 Sep;48(9):e70207. doi: 10.1002/clc.70207.
Abstract
摘要
相似文献
1
Critique on "Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification".对“使用EHRA（评估心脏瓣膜、风湿性或人工瓣膜）分类法评估心房颤动患者原生瓣膜疾病的存在情况”的评论
Clin Cardiol. 2025 Sep;48(9):e70207. doi: 10.1002/clc.70207.
2
Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification.使用EHRA（评估心脏瓣膜、风湿性或人工瓣膜）分类法评估心房颤动患者中天然瓣膜疾病的存在情况。
Clin Cardiol. 2025 Aug;48(8):e70172. doi: 10.1002/clc.70172.
3
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).心房颤动伴瓣膜性心脏病的抗栓治疗：欧洲心律协会（EHRA）和欧洲心脏病学会血栓工作组的联合共识文件的执行摘要，得到 ESC 瓣膜性心脏病工作组、南非心脏协会（SA Heart）、心律学会（HRS）、亚太心律学会（APHRS）、心脏心律失常学会（Cardiac Arrhythmia Society of Southern Africa，CASSA）和拉丁美洲心脏刺激和电生理学会（SOLEACE）的认可。
Thromb Haemost. 2017 Dec;117(12):2215-2236. doi: 10.1160/TH-17-10-0709. Epub 2017 Dec 6.
4
Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.根据 EHRA 瓣膜性心脏病分类，心房颤动患者的中风、血栓栓塞和出血。
Int J Cardiol. 2018 Jun 1;260:93-98. doi: 10.1016/j.ijcard.2018.03.017. Epub 2018 Mar 7.
5
Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.心房颤动合并 EHRA 2 型瓣膜性心脏病患者的血栓栓塞和大出血：约旦心房颤动（JoFib）研究。
Vasc Health Risk Manag. 2023 Mar 18;19:145-155. doi: 10.2147/VHRM.S387477. eCollection 2023.
6
Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.心房颤动和心脏瓣膜病患者的卒中与出血风险评分：在全国范围内队列研究中评估“心脏瓣膜病”。
Europace. 2019 Jan 1;21(1):33-40. doi: 10.1093/europace/euy151.
8
Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease.非抗凝治疗的心房颤动合并心脏瓣膜病患者的血栓栓塞风险
JACC Clin Electrophysiol. 2020 Dec 14;6(13):1672-1682. doi: 10.1016/j.jacep.2020.07.005. Epub 2020 Aug 28.
9
Clinical outcomes in recently diagnosed atrial fibrillation related to mitral stenosis compared to non-valvular atrial fibrillation.与非瓣膜性心房颤动相比，近期诊断出的二尖瓣狭窄相关心房颤动的临床结局。
Front Cardiovasc Med. 2025 Jun 18;12:1555557. doi: 10.3389/fcvm.2025.1555557. eCollection 2025.
10
Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin.接受华法林治疗的伴有EHRA 2型瓣膜性心脏病的房颤患者的最佳国际标准化比值（INR）水平。
J Arrhythm. 2020 Apr 15;36(3):425-429. doi: 10.1002/joa3.12342. eCollection 2020 Jun.
本文引用的文献
1
Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification.使用EHRA（评估心脏瓣膜、风湿性或人工瓣膜）分类法评估心房颤动患者中天然瓣膜疾病的存在情况。
Clin Cardiol. 2025 Aug;48(8):e70172. doi: 10.1002/clc.70172.
2
Anticoagulation in Atrial Fibrillation With Valvular Heart Disease.瓣膜性心脏病合并心房颤动的抗凝治疗
J Am Heart Assoc. 2025 Feb 18;14(4):e038736. doi: 10.1161/JAHA.124.038736. Epub 2025 Feb 14.
3
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
4
Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.根据 EHRA 瓣膜性心脏病分类，心房颤动患者的中风、血栓栓塞和出血。
Int J Cardiol. 2018 Jun 1;260:93-98. doi: 10.1016/j.ijcard.2018.03.017. Epub 2018 Mar 7.
5
Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.非维生素K拮抗剂口服抗凝药与华法林对心房颤动合并瓣膜性心脏病患者的影响：一项系统评价和荟萃分析。
J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835.
6
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.ENGAGE AF-TIMI 48 试验中服用依度沙班或华法林的瓣膜性心脏病患者。
J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031.
Zotero 插件